TheEdgeResearch
Home / Stocks / BXPHF

Botanix Pharmaceuticals Limited (BXPHF)

OTC Healthcare Biotechnology
$0.01 ▲ +0.00%
Market Cap
$29.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.86
52-Wk Range
0.01-0.1341
CEO
Howie McKibbon
Country
AU
Currency
USD

Botanix Pharmaceuticals Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $29.8M. On trailing twelve-month figures it carries a trailing P/E of -0.56, a net margin of -202.2%. Its beta of 0.86 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.56
Price / Sales
1.04
Price / Book
0.68
EV / EBITDA
-0.21
Gross margin
-172.2%
Operating margin
-200.8%
Net margin
-202.2%
Return on equity
—
Debt / equity
0.23
Current ratio
2.59
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
11
IPO date
2019-09-09
Headquarters
Melbourne, VIC, AU
About Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Ltd is a dermatology company that focuses on developing safe and effective topical treatments for serious skin conditions. The company's product pipeline includes treatments for conditions such as moderate to severe acne, atopic dermatitis, rosacea, and axillary hyperhidrosis. It has an exclusive license to use a proprietary drug delivery system for skin diseases.

Comparable companies

Botanix Pharmaceuticals Limited is most often compared with the following Healthcare names:

AAWHBRIBFHOFBFIPHYFJWCTFKNTPFMLLCFNDTPNGENFSCNLF
More research on BXPHF
BXPHF technical analysis BXPHF TheEdge Score Compare against peers
Open full interactive analysis & DCF →